Aptar Announces Gael Touya as Its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year

Why It Matters

The leadership change positions a proven insider to accelerate Aptar’s growth strategy, particularly in high‑margin pharma and expanding consumer markets, while ensuring continuity after a period of strong financial performance and strategic acquisitions.

Summary

AptarGroup announced that Gael Touya, a 30‑year veteran who has led Aptar Pharma to about 82% top‑line growth, will become President and Chief Executive Officer on September 1, 2026, succeeding Stephan B. Tanda, who will retire from the board by year‑end after a seven‑year tenure that lifted adjusted EBITDA margins to roughly 22% and doubled adjusted EPS. Touya will also join the board as a director, while Tanda will serve as an advisor through the transition. The board highlighted Touya’s global commercial, operational and technical experience across Aptar’s pharma, consumer, and beauty businesses as key to driving the next phase of growth and extending success in regulated drug delivery to broader consumer segments.